Stem cell transplantation after reduced-intensity conditioning for sickle cell disease

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 308-312

  Matthes Martin, Susanne ^a   Lawitschka, Anita ^a   Fritsch, Gerhard ^a   Lion, Thomas ^a   Grimm, Brigitte ^a   Breuer, Sabine ^a   Boztug, Heidrun ^a   Karlhuber, Susanne ^a   Holter, Wolfgang ^a   Peters, Christina ^a   Minkov, Milen ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Children; Reduced intensity conditioning; Sickle cell disease; Stem cell transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CD34 ANTIGEN; CYCLOSPORIN A; FAMCICLOVIR; FLUDARABINE; HEMOGLOBIN S; IMMUNOGLOBULIN G; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHICKENPOX; CHILD; CHIMERA; CLINICAL ARTICLE; CONVALESCENCE; DISEASE SEVERITY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HERPES VIRUS INFECTION; HUMAN; LYMPH NODE IRRADIATION; MALE; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SIBLING; SICKLE CELL ANEMIA; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, SICKLE CELL; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; SIBLINGS; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875254453     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12082     Document Type: Article

References (47)

1. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-72.
2. Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 2006;173:1264-9.
3. Ngo C, Kayem G, Habibi A, Benachi A, Goffinet F, Galacteros F, Haddad B. Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. Eur J Obstet Gynecol Reprod Biol 2010;152:138-42.
4. Wang WC. Sickle-cell disease and compromised cognition. Pediatr Blood Cancer 2011;56:705-6.
5. van der Plas EM, van den Tweel XW, Geskus RB, Heijboer H, Biemond BJ, Peters M, Fijnvandraat K. Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. Br J Haematol 2011;155:106-10.
6. Anoop PB, Bevan DH, Chakrabarti S. Usefulness and limitations of Bayesian network model as a mortality risk assessment tool in sickle cell anemia. Am J Hematol 2009;84:312-3.
7. Becton LJ, Kalpatthi RV, Rackoff E, Disco D, Orak JK, Jackson SM, Shatat IF. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 2010;25:1505-11.
8. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
9. McClish DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes 2005;3:50.
10. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447-52.
11. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
12. Lucarelli G, Gaziev J, Isgro A, et al. Allogeneic cellular gene therapy in hemoglobinopathies-evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplant 2011;47:227-30.
13. Majumdar S, Robertson Z, Robinson A, Starnes S, Iyer R, Megason G. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant 2010;45:895-900.
14. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007;137:479-85.
15. Bernaudin F, Robin M, Ferry C. TC-related myeloablative stem cell transplantation (SCT) to cure sickle cell anemia (SCA): update of French results. Blood 2010;116:abstract 3518.
16. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998;22:1-6.
17. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007;110:2749-56.
18. Brachet C, Azzi N, Demulder A, et al. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome. Bone Marrow Transplant 2004;33:799-803.
19. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003;101:2137-43.
20. Brachet C, Heinrichs C, Tenoutasse S, Devalck C, Azzi N, Ferster A. Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2007;29:445-50.
21. Walters MC, Sullivan KM. Stem-cell transplantation for sickle cell disease. N Engl J Med 2010;362:955-6; author reply 6.
22. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with post-transplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285-91.
23. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005;35:171-7.
24. Horwitz ME, Spasojevic I, Morris A, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant 2007;13:1422-6.
25. Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-17.
26. Krishnamurti L, Kharbanda S, Biernacki MA, Zhang W, Baker KS, Wagner JE, Wu CJ. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008;14:1270-8.
27. van Besien K, Koshy M, Anderson-Shaw L, Talishy N, Dorn L, Devine S, Yassine M, Kodish E. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant 2001;28:545-9.
28. Lion T, Kosulin K, Landlinger C, et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 2010;24:706-14.
29. Breuer S, Rauch M, Matthes-Martin S, Lion T. Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther 2012;16:63-77.
30. Lion T, Watzinger F, Preuner S, et al. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia 2012;26:1821-8.
31. McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011;46:27-33.
32. van Beers EJ, van Tuijn CF, Mac Gillavry MR, van der Giessen A, Schnog JJ, Biemond BJ. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 2008;93:757-60.
33. Matthes-Martin S, Potschger U, Bergmann K, Frommlet F, Brannath W, Bauer P, Klingebiel T. Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008;14:335-43.
34. Chakrabarti S, Bareford D. A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease. Bone Marrow Transplant 2007;39:447-51.
35. Boztug H, Karitnig-Weiss C, Ausserer B, et al. Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen. Pediatr Hematol Oncol 2012;29:585-94.
36. Gennery AR, Khawaja K, Veys P, et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 2004;103:1152-7.
37. Lawitschka A, Peters C, Seidel MG, Havranek A, Heitger A, Fazekas T, Gueclue ED, Gadner H, Matthes-Martin S. Long-term remission in pediatric Wegener granulomatosis following allo-SCT after reduced-intensity conditioning. Bone Marrow Transplant 2011;46:462-3.
38. Matthes-Martin S, Lion T, Haas OA, et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003;17:1934-42.
39. Seidel MG, Fritsch G, Lion T, Jurgens B, Heitger A, Bacchetta R, Lawitschka A, Peters C, Gadner H, Matthes-Martin S. Selective engraftment of donor CD4 + 25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood 2009;113:5689-91.
40. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215-25.
41. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A, Amylon M, Sullivan KM, Storb RF, Walters MC. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003;9:519-28.
42. van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, Sosman J, Chen YH, Koshy M, Hoffman R. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 2000;26:445-9.
43. Krishnamurti L, Abel S, Maiers M, Flesch S. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003;31:547-50.
44. Andreani M, Testi M, Gaziev J, et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 2011;96:128-33.
45. Wu CJ, Gladwin M, Tisdale J, et al. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol 2007;139:504-7.
46. Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W, Antin JH, Ritz J. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood 2005;106:3639-45.
47. Locatelli F, Pagliara D. Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease. Pediatr Blood Cancer 2012;59:372-6.